Rapid and sustained relief from the symptoms of carcinoid syndrome: Results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide - Ruszniewski, P; Ish-Shalom, S; Wymenga, M (Neuroendocrinology, 2004)
et al.